Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience

Cordova-Delgado, Miguel; Pinto, Mauricio P.; Regonesi, Carlos; Cereceda, Luis; Reyes, Jose Miguel; Itriago, Laura; Majlis, Alejandro; Rodriguez, Pablo; Fassler, Andre; Mahave, Mauricio; Leon, Maria Elisa; Gallardo, Jorge; Rodriguez, Maria Paz Z.; Berkovits, Alejandro; Manque, Patricio; et. al.

Abstract

Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and "biomarker-driven" treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports are based on developed countries and usually involve metastatic, hard-to-treat or incurable cancer patients. Moreover, in many cases race and ethnicity in these studies is commonly unreported and real-world evidence in this topic is scarce. Herein, we report data from a total of 202 Chilean advanced stage refractory cancer patients. Retrospectively, we collected patient data from NGS tests and IHC in order to determine the proportion of patients that would benefit from targeted treatments. Overall >20 tumor types were included in our cohort and 37% of patients (n = 74) displayed potentially actionable alterations, including on-label, off-label and immune checkpoint inhibitor recommendations. Our findings were in-line with previous reports such as the cancer genome atlas (TCGA). To our knowledge, this is the first report of its kind in Latin America delivering real-world evidence to estimate the percentage of refractory tumor patients that might benefit from precision oncology. Although this approach is still in its infancy in Chile, we strongly encourage the implementation of mutational tumor boards in our country in order to provide more therapeutic options for advanced stage refractory patients.

Más información

Título según WOS: Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience
Título de la Revista: JOURNAL OF PERSONALIZED MEDICINE
Volumen: 12
Número: 2
Editorial: MDPI
Fecha de publicación: 2022
DOI:

10.3390/jpm12020195

Notas: ISI